SCHEMBL141541

SCHEMBL141541

CC(O)N(c1nc(N2CCCCC2)c2nc(N(C(C)O)C(C)O)nc(N3CCCCC3)c2n1)C(C)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 14/20 0.54
ALDH1A1 P00352 3/20 0.54
LMNA P02545 2/20 0.54
TSHR P16473 2/20 0.54
PDE4A P27815 2/20 0.54
PDE4B Q07343 2/20 0.54
PDE4C Q08493 2/20 0.54
PDE4D Q08499 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
PDE2A O00408 1/20 0.54
RGS12 O14924 1/20 0.54
SLC22A2 O15244 1/20 0.54
SLC22A1 O15245 1/20 0.54
ABCC4 O15439 1/20 0.54
ABCC5 O15440 1/20 0.54
PDE6D O43924 1/20 0.54
PDE8A O60658 1/20 0.54
GMNN O75496 1/20 0.54
USP2 O75604 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3395769 1.00 SLC29A1 (0.54) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL15065643 0.93 SLC29A1 (0.48) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL7446838 0.91 SLC29A1 (0.47) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL9565592 0.90 SLC29A1 (0.49) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL11564661 0.85 SLC29A1 (0.42) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL9351966 0.85 SLC29A1 (0.56) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL1956785 0.85 SLC29A1 (0.41) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL2459706 0.84 SLC29A1 (0.41) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL2458640 0.84 SLC29A1 (0.41) SLC29A1ALDH1A1LMNATSHRPDE4A
SCHEMBL4077875 0.84 SLC29A1 (0.43) SLC29A1ALDH1A1LMNATSHRPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220087970-A1 PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION THE JOHNS HOPKINS UNIVERSTY 2022-03-24 US claimed
WO-2020150698-A1 PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2020-07-23 WO claimed
US-5346772-A HAVING A HIGH LUMINANCE AND HIGH EMISSION EFFICIENCY PIONEER ELECTRONIC CORPORATION (JP) 1994-09-13 US claimed
EP-0123841-B1 MEDICAMENT WITH AN ATHEROPROTECTIVE HIGH DENSITY LIPOPROTEIN ENHANCING ACTIVITY, CONTAINING 2,6-BIS-DIETHANOLAMINO-4,8-DIPIPERIDINOPYRIMIDE (5,4-D) PYRIMIDINE Dr. Karl Thomae GmbH (DE) 1989-09-20 EP claimed
EP-0019586-A1 Antithrombotic combination formulas CIBA-GEIGY AG (CH) 1980-11-26 EP claimed
EP-0000774-A1 Antithrombotic medicative combination and process for its preparation Dr. Karl Thomae GmbH (DE) 1979-02-21 EP claimed
JP-7258084-A None JP disclosed
JP-55147295-A None JP disclosed
JP-57209291-A None JP disclosed
US-20230149427-A1 COMPOSITIONS COMPRISING COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE WITH TROMETHAMINE AND METHODS OF USE THEAPRIN PHARMACEUTICALS, INC. 2023-05-18 US disclosed
US-20220087970-A1 PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION THE JOHNS HOPKINS UNIVERSTY 2022-03-24 US disclosed
WO-2020150698-A1 PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2020-07-23 WO disclosed
US-10357453-B2 Methods of eye treatment using therapeutic compositions containing dipyridamole O.D. OCULAR DISCOVERY LTD. (IL) 2019-07-23 US disclosed
EP-0019586-A1 Antithrombotic combination formulas CIBA-GEIGY AG (CH) 1980-11-26 EP disclosed
JP-S55147295-A PREPARATION OF DIPHOSPHOGLYCERIC ACID SALT NIPPON SHINYAKU CO LTD 1980-11-17 JP disclosed
US-4206214-A Antithrombotic pharmaceutical compositions containing dipyridamole and sulfinpyrazone BOEHRINGER INGELHEIM GMBH (DE) 1980-06-03 US disclosed
EP-0000774-B1 ANTITHROMBOTIC MEDICATIVE COMBINATION AND PROCESS FOR ITS PREPARATION Dr. Karl Thomae GmbH (DE) 1980-05-28 EP disclosed
US-4174395-A 4-[4-(2-Methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl-methyl)-1-piperazinyl]-6-methylpyrimidines SOCIETE CIVILE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 1979-11-13 US disclosed
EP-0000774-A1 Antithrombotic medicative combination and process for its preparation Dr. Karl Thomae GmbH (DE) 1979-02-21 EP disclosed
US-3961071-A CARDIOVASCULAR DISORDERS, 1-PHENOXY-2-HYDROXY-3-TERT-BUTYLAMINO PROPANES BOEHRINGER INGELHEIM GMBH (DT) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149427-A1 COMPOSITIONS COMPRISING COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE WITH TROMETHAMINE AND METHODS OF USE PTGIS, PTGES, PTGS1 SLC29A1 258/4885ALDH1A1 418/4885LMNA 4565/4885
US-20220087970-A1 PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION PYGB, PRKG1, ACHE SLC29A1 2272/4885ALDH1A1 1525/4885LMNA 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.